Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
OTLK logo OTLK
Upturn stock ratingUpturn stock rating
OTLK logo

OUTLOOK THERAPEUTICS INC (OTLK)

Upturn stock ratingUpturn stock rating
$1.6
Last Close (24-hour delay)
Profit since last BUY16.13%
upturn advisory
SELL
SELL since 3 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: OTLK (1-star) is a SELL. SELL since 3 days. Profits (16.13%). Updated daily EoD!

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

6 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $8.6

1 Year Target Price $8.6

Analysts Price Target For last 52 week
$8.6Target price
Low$0.87
Current$1.6
high$9.25

Analysis of Past Performance

Type Stock
Historic Profit -40.39%
Avg. Invested days 37
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 71.14M USD
Price to earnings Ratio 0.41
1Y Target Price 8.6
Price to earnings Ratio 0.41
1Y Target Price 8.6
Volume (30-day avg) 6
Beta 0.31
52 Weeks Range 0.87 - 9.25
Updated Date 07/1/2025
52 Weeks Range 0.87 - 9.25
Updated Date 07/1/2025
Dividends yield (FY) -
Basic EPS (TTM) 3.94

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -122.34%
Return on Equity (TTM) -3.65%

Valuation

Trailing PE 0.41
Forward PE 2.85
Enterprise Value 94328052
Price to Sales(TTM) 13.27
Enterprise Value 94328052
Price to Sales(TTM) 13.27
Enterprise Value to Revenue 26.1
Enterprise Value to EBITDA -4.13
Shares Outstanding 42853700
Shares Floating 20905158
Shares Outstanding 42853700
Shares Floating 20905158
Percent Insiders 38.31
Percent Institutions 16.81

Analyst Ratings

Rating 3
Target Price 8.6
Buy 1
Strong Buy 4
Buy 1
Strong Buy 4
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

OUTLOOK THERAPEUTICS INC

stock logo

Company Overview

overview logo History and Background

Outlook Therapeutics, Inc., formerly known as Innovus Pharmaceuticals, Inc., was founded in 2003 and focuses on developing and commercializing ophthalmic products. It has gone through several strategic shifts, now concentrating on ONS-5010, an ophthalmic formulation of bevacizumab for various retinal indications.

business area logo Core Business Areas

  • Ophthalmic Therapeutics: Development and commercialization of ONS-5010 (Lytenava), an ophthalmic formulation of bevacizumab, for the treatment of retinal diseases.

leadership logo Leadership and Structure

The leadership team includes Russell Trenary as CEO, Mark Joseph Funari as CFO and the company has a Board of Directors overseeing strategic decisions.

Top Products and Market Share

overview logo Key Offerings

  • Lytenava (ONS-5010): Lytenava (bevacizumab-vikg) is an ophthalmic formulation of bevacizumab under regulatory review for wet AMD. Its primary competition includes biologics such as aflibercept (Eylea) from Regeneron and ranibizumab (Lucentis) from Genentech (Roche). Estimated future market share will depend on FDA approval and market uptake. Revenue is currently zero as it is not yet approved, revenue will grow after commercialization.

Market Dynamics

industry overview logo Industry Overview

The ophthalmic therapeutics market is driven by an aging population and increasing prevalence of retinal diseases such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). The market is competitive, with established players and emerging therapies.

Positioning

Outlook Therapeutics aims to compete in the anti-VEGF market with Lytenava, potentially offering a lower-cost alternative and a differentiated formulation. Its competitive advantage lies in the potential for reduced systemic exposure due to its ophthalmic formulation.

Total Addressable Market (TAM)

The global wet AMD market is estimated to reach billions of dollars. Outlook Therapeutics is positioned to capture a portion of this TAM with Lytenava, contingent on FDA approval and successful commercialization.

Upturn SWOT Analysis

Strengths

  • Potential first FDA-approved ophthalmic bevacizumab
  • Targeting a large and growing market (wet AMD)
  • Specific formulation potentially reducing systemic exposure
  • Orphan drug designation for certain indications offering market exclusivity

Weaknesses

  • Reliance on a single product (ONS-5010/Lytenava)
  • Regulatory approval uncertainty
  • Competition from established anti-VEGF therapies (Eylea, Lucentis)
  • Limited commercial infrastructure currently in place
  • History of rejected FDA application

Opportunities

  • Expansion to other retinal disease indications (DME, RVO)
  • Strategic partnerships for commercialization
  • Market access agreements with payers
  • Geographic expansion into international markets

Threats

  • Failure to obtain FDA approval
  • Delayed or unfavorable reimbursement decisions
  • Emergence of biosimilars or competing therapies
  • Clinical trial setbacks
  • Financial instability or inability to raise capital

Competitors and Market Share

competitor logo Key Competitors

  • REGN
  • ROCHE (ROG.SW)

Competitive Landscape

Outlook Therapeutics competes with established players like Regeneron and Roche in the anti-VEGF market. Its advantage lies in its unique ophthalmic formulation, potentially offering a differentiated safety profile.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by R&D advancements and regulatory milestones rather than revenue generation.

Future Projections: Future growth depends on successful commercialization of ONS-5010. Analyst estimates vary based on approval timelines and market penetration.

Recent Initiatives: Recent initiatives include completing clinical trials for ONS-5010, preparing regulatory submissions, and securing financing.

Summary

Outlook Therapeutics is a development-stage pharmaceutical company focused on ophthalmic treatments, specifically ONS-5010 for wet AMD. Its success hinges on securing FDA approval and effectively competing with established anti-VEGF therapies. The company's financial health depends on continuous funding. Outlook needs to address regulatory setbacks and secure its financial future, as it navigates a competitive market with established players.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings (SEC)
  • Industry Reports
  • Analyst Estimates

Disclaimers:

The information provided is for informational purposes only and does not constitute investment advice. Market conditions and company-specific factors can change rapidly. All investments involve risk.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About OUTLOOK THERAPEUTICS INC

Exchange NASDAQ
Headquaters Iselin, NJ, United States
IPO Launch date 2016-05-13
EVP, CFO, Interim CEO, Treasurer, Secretary & Director Mr. Lawrence A. Kenyon CPA
Sector Healthcare
Industry Biotechnology
Full time employees 23
Full time employees 23

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey.